Literature DB >> 18621417

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.

Ellen van der Spek1, Andries C Bloem, Henk M Lokhorst, Berris van Kessel, Lijnie Bogers-Boer, Niels W C J van de Donk.   

Abstract

The effects of the combination of simvastatin and lenalidomide were analyzed in myeloma. Myeloma cell lines and patient myeloma cells were incubated with different concentrations of lenalidomide, simvastatin, or the combination. Co exposure to simvastatin and lenalidomide resulted in a synergistic reduction of cell viability in myeloma cells. This effect was due to induction of apoptosis and inhibition of proliferation. The combination augmented induction of caspase-8 cleavage and enhanced down-regulation of pStat3. Mevalonate and GGOH abrogated the synergy between lenalidomide and simvastatin. These data provide a rationale for the clinical evaluation of lenalidomide and simvastatin in patients with myeloma.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18621417     DOI： 10.1016/j.leukres.2008.06.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  11 in total

1.  Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

Authors:  Chisako Urata; Mariko Yoshimura; Hidekazu Itamura; Takashi Hisatomi; Yasushi Kubota; Noriyasu Fukushima; Eisaburo Sueoka; Shinya Kimura
Journal:  Int J Hematol       Date:  2011-08-03       Impact factor: 2.490

2.  Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Authors:  Jaime L Shahan; Lori D Panu; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2012-11-28       Impact factor: 2.490

3.  Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival.

Authors:  Alessandra Musso; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

4.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

5.  Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Authors:  Inger S Nijhof; Jeroen J Lammerts van Bueren; Berris van Kessel; Pascale Andre; Yannis Morel; Henk M Lokhorst; Niels W C J van de Donk; Paul W H I Parren; Tuna Mutis
Journal:  Haematologica       Date:  2014-12-15       Impact factor: 9.941

6.  A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.

Authors:  Li Lin; Don M Benson; Stephanie DeAngelis; Courtney E Bakan; Pui-Kai Li; Chenglong Li; Jiayuh Lin
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

7.  Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Sarah A Holstein; Huaxiang Tong; Raymond J Hohl
Journal:  Leuk Res       Date:  2009-07-30       Impact factor: 3.156

8.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

9.  The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis.

Authors:  J Follet; L Corcos; G Baffet; F Ezan; F Morel; B Simon; C Le Jossic-Corcos
Journal:  Br J Cancer       Date:  2012-01-31       Impact factor: 7.640

10.  Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Authors:  Shigeki Ito; Tatsuo Oyake; Kazunori Murai; Yoji Ishida
Journal:  Case Rep Hematol       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.